Christophe Marques, MD
Radiation Oncology · New Orleans, LANPI 1104288216
Payments from drug & device makers
What this record shows
Reflexion Medical, Inc. accounts for 77.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $2,370 and has fallen 88.6% since, to $271 in 2025. Among radiation oncology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 17 payments — averaging $181.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Reflexion Medical, Inc.$2K
- Merck$234
- Myriad Genetic Laboratories, Inc.$152
- Bioprotect Medical, Inc.$135
- AstraZeneca$117
- Progenics Pharmaceuticals, Inc.$61
What the payments were for
- Travel & lodging$1,64553%
- Food & beverage$1,44747%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Reflexion Medical, Inc. | 7 | $2,393 |
| Merck | 2 | $234 |
| Myriad Genetic Laboratories, Inc. | 5 | $152 |
| Bioprotect Medical, Inc. | 1 | $135 |
| AstraZeneca | 1 | $117 |
| Progenics Pharmaceuticals, Inc. | 1 | $61 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,092 in reported general payments places this provider in the 90th percentile of 58 radiation oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 62 | $376 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in New Orleans
- Kareem FakhouryNew Orleans$905
- Troy ScrogginsNew Orleans$850
- Jill VincentNew Orleans$709
- Ellen ZakrisNew Orleans$527
- Ashley BrownNew Orleans$470
- Clayton SmithNew Orleans$384
- Roland HawkinsNew Orleans$182
- Donald MullerNew Orleans$18
- Chiachien WangShreveport$31K
- James RussoLafayette$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.